期刊
BLOOD
卷 111, 期 3, 页码 981-986出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2007-05-088500
关键词
-
类别
资金
- NCI NIH HHS [R01 CA031615, R01 CA31615-25] Funding Source: Medline
- NHLBI NIH HHS [P01 HL078784, P01 HL 78784-03] Funding Source: Medline
- NIDDK NIH HHS [R01 DK49855-14, R01 DK049855] Funding Source: Medline
The study of thrombopoiesis has evolved greatly since an era when platelets were termed the dust of the blood, only about 100 years ago. During this time megakaryocytes were identified as the origin of blood platelets; marrow-derived megakaryocytic progenitor cells were functionally defined and then purified; and the primary regulator of the process, thrombopoietin, was cloned and characterized and therapeutic thrombopoietic agents developed. During this journey we continue to learn that the physiologic mechanisms that drive proplatelet formation can be recapitulated in cell-free systems and their biochemistry evaluated; the molecular underpinnings of endomitosis are being increasingly understood; the intracellular signals sent by engagement of a large number of megakaryocyte surface receptors have been defined; and many of the transcription factors that drive megakaryocytic fate determination have been identified and experimentally manipulated. While some of these biologic processes mimic those seen in other cell types, megakaryocytes and platelets possess enough unique developmental features that we are virtually assured that continued study of thrombopoiesis will yield innumerable clinical and scientific insights for many decades to come.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据